Volume | 775,076 |
|
|||||
News | - | ||||||
Day High | 21.235 | Low High |
|||||
Day Low | 20.475 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Syndax Pharmaceuticals Inc | SNDX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
20.59 | 20.475 | 21.235 | 21.06 | 20.57 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
9,804 | 775,076 | US$ 20.86 | US$ 16,169,351 | - | 11.215 - 25.34 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
16:32:51 | priorref | 87,000 | US$ 21.06 | USD |
Syndax Pharmaceuticals (SNDX) Options Flow Summary
Syndax Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.79B | 84.97M | - | 0 | -209.36M | -2.46 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Syndax Pharmaceuticals News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SNDX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 20.41 | 21.54 | 20.13 | 20.83 | 686,520 | 0.65 | 3.18% |
1 Month | 23.67 | 24.375 | 20.13 | 21.95 | 889,243 | -2.61 | -11.03% |
3 Months | 20.83 | 25.34 | 20.085 | 22.67 | 1,091,847 | 0.23 | 1.10% |
6 Months | 11.99 | 25.34 | 11.96 | 19.86 | 1,357,208 | 9.07 | 75.65% |
1 Year | 21.08 | 25.34 | 11.215 | 18.51 | 1,292,153 | -0.02 | -0.09% |
3 Years | 15.32 | 29.86 | 11.215 | 19.36 | 861,365 | 5.74 | 37.47% |
5 Years | 6.81 | 29.86 | 5.35 | 18.85 | 693,237 | 14.25 | 209.25% |
Syndax Pharmaceuticals Description
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. |